Species differences in drug transporters and implications for translating preclinical findings to humans.
about
How drugs get into cells: tested and testable predictions to help discriminate between transporter-mediated uptake and lipoidal bilayer diffusionA cellular model to study drug-induced liver injury in nonalcoholic fatty liver disease: Application to acetaminophenPurvalanol A, olomoucine II and roscovitine inhibit ABCB1 transporter and synergistically potentiate cytotoxic effects of daunorubicin in vitroDrug target mining and analysis of the Chinese tree shrew for pharmacological testingMetabolism of skin-absorbed resveratrol into its glucuronized form in mouse skin.Placental transporter localization and expression in the Human: the importance of species, sex, and gestational age differences†.A Human Renal Proximal Tubule Cell Line with Stable Organic Anion Transporter 1 and 3 Expression Predictive for Antiviral-Induced Toxicity.Species differences in the pharmacokinetics of cefadroxil as determined in wildtype and humanized PepT1 miceInterindividual variability in hepatic organic anion-transporting polypeptides and P-glycoprotein (ABCB1) protein expression: quantification by liquid chromatography tandem mass spectroscopy and influence of genotype, age, and sexIntracellular drug concentrations and transporters: measurement, modeling, and implications for the liver.Herb-drug interactions: challenges and opportunities for improved predictions.In vitro methods to support transporter evaluation in drug discovery and development.Organs-on-a-chip: a new tool for drug discovery.Structure and function of BCRP, a broad specificity transporter of xenobiotics and endobiotics.In vitro and in vivo approaches to characterize transporter-mediated disposition in drug discovery.Novel pre-clinical methodologies for pharmacokinetic drug-drug interaction studies: spotlight on "humanized" animal models.Applications of physiologically based pharmacokinetic modeling for the optimization of anti-infective therapies.3D functional and perfusable microvascular networks for organotypic microfluidic models.Transporter assays as useful in vitro tools in drug discovery and development.Intrahepatic Sampling for the Elucidation of Antiviral Clinical Pharmacology.Modeling the Human Scarred Heart In Vitro: Toward New Tissue Engineered Models.Challenges in nasal drug absorption: how far have we come?Refinement, Reduction, and Replacement of Animal Toxicity Tests by Computational Methods.Renal Drug Transporters and Drug Interactions.Maintenance of drug metabolism and transport functions in human precision-cut liver slices during prolonged incubation for 5 days.Rifampin-Mediated Induction of Tamoxifen Metabolism in a Humanized PXR-CAR-CYP3A4/3A7-CYP2D6 Mouse Model.Evaluation of [18F]MC225 as a PET radiotracer for measuring P-glycoprotein function at the blood-brain barrier in rats: Kinetics, metabolism, and selectivity.Cardiovascular Organ-on-a-Chip Platforms for Drug Discovery and Development.A Role for 3D Printing in Kidney-on-a-Chip Platforms.Paritaprevir and Ritonavir Liver Concentrations in Rats as Assessed by Different Liver Sampling Techniques.Human kidney proximal tubule-on-a-chip for drug transport and nephrotoxicity assessment.The conditional stimulation of rat organic cation transporter 2, but not its human ortholog, by mesoridazine: the possibility of the involvement of the high-affinity binding site of the transporter in the stimulation.Species Differences in Human and Rodent PEPT2-Mediated Transport of Glycylsarcosine and Cefadroxil in Pichia Pastoris Transformants.Quantification of Four Efflux Drug Transporters in Liver and Kidney Across Species Using Targeted Quantitative Proteomics by Isotope Dilution NanoLC-MS/MS.Pharmacokinetics and Disposition of the Thiouracil Derivative PF-06282999, an Orally Bioavailable, Irreversible Inactivator of Myeloperoxidase Enzyme, Across Animals and Humans.Predicting Oral Drug Absorption: Mini Review on Physiologically-Based Pharmacokinetic Models.Generation and Characterization of a Breast Cancer Resistance Protein Humanized Mouse Model.Breast Cancer Resistance Protein and Multidrug Resistance Protein 2 Regulate the Disposition of Acacetin Glucuronides.Advances in predictive in vitro models of drug-induced nephrotoxicity.Brain microvascular endothelial-astrocyte cell responses following Japanese encephalitis virus infection in an in vitro human blood-brain barrier model.
P2860
Q24273350-D5F7F084-6301-4A2B-8EF8-F3F358A4F28AQ28396747-31E20823-FE73-411A-A2BF-261F9502E256Q28537944-9609D7A5-9CC4-48C4-8EDA-ECA4D79B83E5Q28541742-201715F2-679D-4472-B3D7-2E7BA74D2F78Q34704230-7247F777-CB0E-4A83-A766-6301D98DEE90Q36322293-82FE8F40-EE42-43A4-BC8C-D3321BF3C255Q36653948-BF94383E-72AE-4E73-98C1-E0939198A44CQ36767617-D20254EC-73DA-4FDB-AE52-F89580BDC5B6Q37422685-5DCE6C39-0C89-4E77-90C3-FE3C2A10E29AQ37504548-44575B8D-7799-4066-9A99-DA0863FFAA8FQ37603890-F6293B70-B1B9-4E97-BE80-BC84304CF518Q38099194-71C1C766-7145-416E-AC76-C246C3ABD190Q38195304-E0772611-4AC2-4C61-9F35-2B081D604285Q38207943-DE6D4C7D-FFF6-4A23-865D-E979F8F5F8E9Q38214334-239C43FF-7F80-4C14-B650-2C020D74E361Q38255685-EF770A96-AF22-4044-B5E1-DAB657220E18Q38420688-DDA8E3E3-8171-4C8C-8718-58E1CFD5A1DDQ38429788-96C5613B-67E0-48A5-906A-7DD138369E67Q38619057-EF347547-99C8-4AA0-80EB-6D6E8F4FBB6EQ38750141-59B0DA83-36C9-47AD-9700-8291E5256CC6Q38788603-2162D655-A28D-4CF0-8FC2-462FA182AC85Q38842805-05FA4144-459F-4F09-B795-B8F048F7F0BEQ39067502-1F47D807-9982-4356-8839-279AAFB1959CQ39140289-22CC5287-8C59-49EF-B538-52CA86A6D8DFQ39310632-419C3316-01F6-4135-88FA-8AC89D0F7C93Q39476381-1380E5B6-0C03-46FD-9B10-65425A7040F1Q39647414-BE31046A-1BF0-4E74-8B4C-00E5F0414D03Q41783099-9EF768BF-1B95-4989-A71B-0D511232BB31Q42330872-70040DEE-181A-418A-AD39-6A0BF9F00D1EQ42358813-A7F62D88-4C27-4345-AD2E-EACECA1A7A2DQ42438111-314BC2C0-0EC5-4E34-B88D-0EA871059C41Q46320921-D7E22349-8813-4EB4-B4A3-1AD667DA83CCQ46460825-9B9B2511-0C94-4D0F-BF6A-D8CD2ADAF81AQ46525620-77B9613D-A8F6-40AC-B5E7-E37BD53D9E17Q46633556-FB89CA4E-1412-423A-9C94-24038E552CA8Q47338381-F048CC4F-B38F-4A54-A4EB-8C50FCF587C9Q48893219-2EB1B24E-B7F6-4515-8E1E-E7336D6192FEQ51050124-5CB7D223-57D6-45CE-BEEA-1A2B3297C7F0Q52601626-398F49D4-645E-4289-A79F-4B1091197207Q52690986-8670D4C3-A057-495B-9257-4FE565FC6979
P2860
Species differences in drug transporters and implications for translating preclinical findings to humans.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Species differences in drug tr ...... reclinical findings to humans.
@en
type
label
Species differences in drug tr ...... reclinical findings to humans.
@en
prefLabel
Species differences in drug tr ...... reclinical findings to humans.
@en
P2093
P2860
P1476
Species differences in drug tr ...... reclinical findings to humans.
@en
P2093
Kelly Bleasby
Raymond Evers
Xiaoyan Chu
P2860
P304
P356
10.1517/17425255.2013.741589
P407
P577
2012-12-21T00:00:00Z